561 related articles for article (PubMed ID: 29551442)
41. Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.
Odds FC
Curr Opin Investig Drugs; 2006 Aug; 7(8):766-72. PubMed ID: 16955689
[TBL] [Abstract][Full Text] [Related]
42. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
43. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.
Guinea J; Bouza E
Future Microbiol; 2008 Dec; 3(6):603-15. PubMed ID: 19072177
[TBL] [Abstract][Full Text] [Related]
44. Isavuconazonium: first global approval.
McCormack PL
Drugs; 2015 May; 75(7):817-22. PubMed ID: 25902926
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan.
Kohno S; Izumikawa K; Takazono T; Miyazaki T; Yoshida M; Kamei K; Ogawa K; Taniguchi S; Akashi K; Tateda K; Mukae H; Miyazaki Y; Okada F; Kanda Y; Kakeya H; Suzuki J; Kimura SI; Kishida M; Matsuda M; Niki Y
J Infect Chemother; 2023 Feb; 29(2):163-170. PubMed ID: 36307059
[TBL] [Abstract][Full Text] [Related]
46. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.
Furfaro E; Signori A; Di Grazia C; Dominietto A; Raiola AM; Aquino S; Ghiggi C; Ghiso A; Ungaro R; Angelucci E; Viscoli C; Mikulska M
J Antimicrob Chemother; 2019 Aug; 74(8):2341-2346. PubMed ID: 31119272
[TBL] [Abstract][Full Text] [Related]
47. Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.
Schmitt-Hoffmann AH; Kato K; Townsend R; Potchoiba MJ; Hope WW; Andes D; Spickermann J; Schneidkraut MJ
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971866
[TBL] [Abstract][Full Text] [Related]
48. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.
Thompson GR; Wiederhold NP
Mycopathologia; 2010 Nov; 170(5):291-313. PubMed ID: 20524153
[TBL] [Abstract][Full Text] [Related]
49. Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.
Durand ML; Kitt TM; Song Y; Marty FM
Clin Infect Dis; 2021 Sep; 73(6):e1380-e1383. PubMed ID: 33914864
[TBL] [Abstract][Full Text] [Related]
50. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
Kovanda LL; Petraitiene R; Petraitis V; Walsh TJ; Desai A; Bonate P; Hope WW
J Antimicrob Chemother; 2016 Jul; 71(7):1885-91. PubMed ID: 27084921
[TBL] [Abstract][Full Text] [Related]
51. Voriconazole: therapeutic review of a new azole antifungal.
Herbrecht R
Expert Rev Anti Infect Ther; 2004 Aug; 2(4):485-97. PubMed ID: 15482215
[TBL] [Abstract][Full Text] [Related]
52. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.
Azanza JR; Grau S; Vázquez L; Rebollo P; Peral C; López-Ibáñez de Aldecoa A; López-Gómez V
Mycoses; 2021 Jan; 64(1):66-77. PubMed ID: 32989796
[TBL] [Abstract][Full Text] [Related]
53. Safety and effectiveness of isavuconazole in real-life non-neutropenic patients.
Monzó-Gallo P; Lopera C; Badía-Tejero AM; Machado M; García-Rodríguez J; Vidal-Cortés P; Merino E; Calderón J; Fortún J; Palacios-Baena ZR; Pemán J; Sanchis JR; Aguilar-Guisado M; Gudiol C; Ramos JC; Sánchez-Romero I; Martin-Davila P; López-Cortés LE; Salavert M; Ruiz-Camps I; Chumbita M; Aiello TF; Peyrony O; Puerta-Alcalde P; Soriano A; Marco F; Garcia-Vidal C
Int J Infect Dis; 2024 Jul; 144():107070. PubMed ID: 38663477
[TBL] [Abstract][Full Text] [Related]
54. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.
Horn D; Goff D; Khandelwal N; Spalding J; Azie N; Shi F; Franks B; Shorr AF
J Med Econ; 2016 Jul; 19(7):728-34. PubMed ID: 26960060
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
Wu X; Clancy CJ; Rivosecchi RM; Zhao W; Shields RK; Marini RV; Venkataramanan R; Nguyen MH
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275091
[TBL] [Abstract][Full Text] [Related]
56. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.
Cornu M; Bruno B; Loridant S; Navarin P; François N; Lanternier F; Amzallag-Bellenger E; Dubos F; Mazingue F; Sendid B
BMC Pharmacol Toxicol; 2018 Dec; 19(1):81. PubMed ID: 30522521
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
Stott KE; Hope WW
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i12-i18. PubMed ID: 28355463
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Petraitis V; Petraitiene R; Moradi PW; Strauss GE; Katragkou A; Kovanda LL; Hope WW; Walsh TJ
Antimicrob Agents Chemother; 2016 May; 60(5):2718-26. PubMed ID: 26883703
[TBL] [Abstract][Full Text] [Related]
59. Isavuconazole shortens the QTc interval.
Mellinghoff SC; Bassetti M; Dörfel D; Hagel S; Lehners N; Plis A; Schalk E; Vena A; Cornely OA
Mycoses; 2018 Apr; 61(4):256-260. PubMed ID: 29178247
[TBL] [Abstract][Full Text] [Related]
60. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.
Floros L; Pagliuca A; Taie AA; Weidlich D; Rita Capparella M; Georgallis M; Sung AH
J Med Econ; 2020 Jan; 23(1):86-97. PubMed ID: 31262225
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
